Biosimilars, data exclusivity and the TPP: Seeking clarity
This article was originally published in SRA
Without the drama of a Rocky movie, the bell rang on the 14th round of the Trans-Pacific Partnership (TPP) on 15 September, with the US heading into the 15th round without a proposal for terms of intellectual property protection for brand-name biologics against biosimilars – although sorting out what the American innovator industry is lobbying for in the trade agreement could leave one as dizzy as taking a few punches to the head1.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.